TY - JOUR
T1 - Stereotactic radiotherapy of histologically proven inoperable stage i non-small cell lung cancer
T2 - Patterns of failure
AU - Andratschke, Nicolaus
AU - Zimmermann, Frank
AU - Boehm, Eva
AU - Schill, Sabine
AU - Schoenknecht, Christine
AU - Thamm, Reinhard
AU - Molls, Michael
AU - Nieder, Carsten
AU - Geinitz, Hans
N1 - Funding Information:
This work was supported by generous financial aid from the “ Bavarian State Ministry of Environment, Public Health and Consumer Protection ”. We thank Barbara Hofbauer, Assistant to the Head of Department, for her help in preparing the manuscript. Appendix A
PY - 2011/11
Y1 - 2011/11
N2 - Background and purpose: To report patterns of failure of stereotactic body radiation therapy (SBRT) in inoperable patients with histologically confirmed stage I NSCLC. Materials and methods: Ninety-two inoperable patients (median age: 75 years) with clinically staged, histologically proven T1 (n = 31) or T2 (n = 61), N0, M0 non-small cell lung cancer (NSCLC) were included in this study. Treatment consisted of 3-5 fractions with 7-15 Gy per fraction prescribed to the 60% isodose. Results: Freedom from local recurrence at 1, 3 and 5 years was 89%, 83% and 83%, respectively. All 10 local failures were observed in patients with T2 tumors. Isolated regional recurrence was observed in 7.6%. The crude rate of distant progression was 20.7%. Overall survival at 1, 3, and 5 years was 79%, 38% and 17% with a median survival of 29 months. Disease specific survival at 1, 3, and 5 years was 93%, 64% and 48%. Karnofsky performance status, T stage, gross tumor volume and tumor location had no significant impact on overall and disease specific survival. SBRT was generally well tolerated and all patients completed therapy as planned. Conclusion: SBRT for stage I lung cancer is very well tolerated in this patient cohort with significant cardiopulmonal comorbidity and results in excellent local control rates, although a considerable portion develops regional and distant metastases.
AB - Background and purpose: To report patterns of failure of stereotactic body radiation therapy (SBRT) in inoperable patients with histologically confirmed stage I NSCLC. Materials and methods: Ninety-two inoperable patients (median age: 75 years) with clinically staged, histologically proven T1 (n = 31) or T2 (n = 61), N0, M0 non-small cell lung cancer (NSCLC) were included in this study. Treatment consisted of 3-5 fractions with 7-15 Gy per fraction prescribed to the 60% isodose. Results: Freedom from local recurrence at 1, 3 and 5 years was 89%, 83% and 83%, respectively. All 10 local failures were observed in patients with T2 tumors. Isolated regional recurrence was observed in 7.6%. The crude rate of distant progression was 20.7%. Overall survival at 1, 3, and 5 years was 79%, 38% and 17% with a median survival of 29 months. Disease specific survival at 1, 3, and 5 years was 93%, 64% and 48%. Karnofsky performance status, T stage, gross tumor volume and tumor location had no significant impact on overall and disease specific survival. SBRT was generally well tolerated and all patients completed therapy as planned. Conclusion: SBRT for stage I lung cancer is very well tolerated in this patient cohort with significant cardiopulmonal comorbidity and results in excellent local control rates, although a considerable portion develops regional and distant metastases.
KW - Lung cancer
KW - Radiation therapy
KW - SBRT
KW - Stage I
KW - Stereotactic radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=81755184340&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2011.06.009
DO - 10.1016/j.radonc.2011.06.009
M3 - Article
C2 - 21724287
AN - SCOPUS:81755184340
SN - 0167-8140
VL - 101
SP - 245
EP - 249
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
IS - 2
ER -
